Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets
Imatinib Mesylate is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE.
New Delhi: Drug firm Lupin on Tuesday said it in alliance with Natco Pharma has received nod from the US health regulator to market generic Imatinib Mesylate tablets used for treatment of certain types of cancer.
The product is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE.
Lupin and Natco Pharma have received final approval from the US Food and Drug Administration (USFDA) to market generic Imatinib Mesylate tablets, 100 mg and 400 mg, the filing said.
As per IQVIA MAT December 2018 data, Imatinib Mesylate tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately USD 655 million in the US, Lupin said.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here